期刊
CANCER LETTERS
卷 321, 期 2, 页码 120-127出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2012.01.014
关键词
Ovarian cancer; Photodynamic therapy; Cetuximab; Verteporfin; Immunoconjugate
类别
资金
- National Institutes of Health [RO1AR40352, 5R01CA160998, PO1CA84203]
- Massachusetts Department of Public Health [34081126112]
- Whitaker Foundation
Targeted photosensitizer delivery to EGFR-expressing cells was achieved in the present study using a high purity, targeted photoimmunoconjugate (PIC). When the PDT agent, benzoporphyrin derivative monoacid ring A (BPD) was coupled to an EGFR-targeting antibody (cetuximab), we observed altered cellular localization and selective phototoxicity of EGFR-positive cells, but no phototoxicity of EGFR-negative cells. Cetuximab in the PIC formulation blocked EGF-induced activation of the EGFR and downstream signaling pathways. Our results suggest that photoimmunotargeting is a useful dual strategy for the selective destruction of cancer cells and also exerts the receptor-blocking biological function of the antibody. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据